SUBSCRIBE
SUBSCRIBE

Phase 2

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Investors Upset as Acorda Abandons Development of Another Drug After Phase II Flop
November 21, 2016
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
Investors Hold Their Breath for the “Most Important Event in Biotech"—Here are 5 Stocks to Watch
November 16, 2016
 · 
2 min read
Antares Pharma Implodes After FDA Responds to Its Xyosted NDA
Drug Development
Puma Biotech Crashes After Diarrhea Risk is Linked to Breast Cancer Drug in Abstract
November 15, 2016
 · 
2 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
3 Reasons That Make Biogen the King of a Crumbling Empire
November 11, 2016
 · 
2 min read
Why AstraZeneca PLC CEO Took a Job His Friends Called a Suicide Mission
Drug Development
AstraZeneca PLC Faces Another R&D Setback as Plans to File for Early Approval for Cancer Med are Scrapped
November 10, 2016
 · 
2 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
FDA Slaps Clinical Hold on Arrowhead Pharma’s Hep B Study
November 9, 2016
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
Sanofi and Novartis AG are the Worst Culprits in Reporting Clinical Trial Data, Shire the Best
November 4, 2016
 · 
2 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Drug Development
Merck & Co.'s Alzheimer’s Contender Wows in Human Clinical Trial
November 3, 2016
 · 
3 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Drug Development
Gilead Drops Another Bombshell, Will Shift R&D Cash Away From Hep C
November 3, 2016
 · 
2 min read
Roche Slammed With Partial Holds for Two Combo Cancer Trials
Drug Development
Four Patients Suffered Serious Adverse Events While on Roche’s Breakthrough Hemophilia Drug
November 3, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
 · 
18 min read
Press Releases
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 7, 2026
 · 
7 min read
Press Releases
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 7, 2026
 · 
1 min read
Press Releases
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 6, 2026
 · 
5 min read
Press Releases
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
 · 
10 min read
Press Releases
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
 · 
14 min read
Press Releases
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
May 6, 2026
 · 
10 min read
Press Releases
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
 · 
12 min read
Press Releases
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
May 6, 2026
 · 
11 min read
Press Releases
Immunocore reports first quarter 2026 financial results and provides a business update
May 6, 2026
 · 
22 min read
Press Releases
Spago Nanomedical’s Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake
May 6, 2026
 · 
3 min read
Press Releases
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
May 6, 2026
 · 
2 min read
Press Releases
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
May 6, 2026
 · 
14 min read
Press Releases
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
May 6, 2026
 · 
5 min read
Press Releases
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 6, 2026
 · 
15 min read
Press Releases
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
May 6, 2026
 · 
10 min read
Press Releases
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
May 6, 2026
 · 
6 min read
Press Releases
Nocion Therapeutics Announces Full Enrollment in Phase 2b ASPIRE Study of Taplucainium for Chronic Cough
May 5, 2026
 · 
3 min read
Press Releases
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
May 5, 2026
 · 
8 min read
Press Releases
Neuraly, Inc. Supports Phase 2 Investigator-Initiated Trial of Pegsebrenatide (NLY01) for Progressive Multiple Sclerosis
May 5, 2026
 · 
3 min read
Load More